N 6 -methyladenosine (m 6 A) is an abundant nucleotide modification in mRNA that is required for the differentiation of mouse embryonic stem cells. However, it remains unknown whether the m 6 A modification controls the differentiation of normal and/or malignant myeloid hematopoietic cells. Here we show that shRNA-mediated depletion of the m 6 A-forming enzyme METTL3 in human hematopoietic stem/progenitor cells (HSPCs) promotes cell differentiation, coupled with reduced cell proliferation. Conversely, overexpression of wild-type METTL3, but not of a catalytically inactive form of METTL3, inhibits cell differentiation and increases cell growth. METTL3 mRNA and protein are expressed more abundantly in acute myeloid leukemia (AML) cells than in healthy HSPCs or other types of tumor cells. Furthermore, METTL3 depletion in human myeloid leukemia cell lines induces cell differentiation and apoptosis and delays leukemia progression in recipient mice in vivo. Single-nucleotide-resolution mapping of m 6 A coupled with ribosome profiling reveals that m 6 A promotes the translation of c-MYC, BCL2 and PTEN mRNAs in the human acute myeloid leukemia MOLM-13 cell line. Moreover, loss of METTL3 leads to increased levels of phosphorylated AKT, which contributes to the differentiation-promoting effects of METTL3 depletion. Overall, these results provide a rationale for the therapeutic targeting of METTL3 in myeloid leukemia.
N 6 -methyladenosine (m 6 A) is an abundant nucleotide modification in mRNA that is required for the differentiation of mouse embryonic stem cells. However, it remains unknown whether the m 6 A modification controls the differentiation of normal and/or malignant myeloid hematopoietic cells. Here we show that shRNA-mediated depletion of the m 6 A-forming enzyme METTL3 in human hematopoietic stem/progenitor cells (HSPCs) promotes cell differentiation, coupled with reduced cell proliferation. Conversely, overexpression of wild-type METTL3, but not of a catalytically inactive form of METTL3, inhibits cell differentiation and increases cell growth. METTL3 mRNA and protein are expressed more abundantly in acute myeloid leukemia (AML) cells than in healthy HSPCs or other types of tumor cells. Furthermore, METTL3 depletion in human myeloid leukemia cell lines induces cell differentiation and apoptosis and delays leukemia progression in recipient mice in vivo. Single-nucleotide-resolution mapping of m 6 A coupled with ribosome profiling reveals that m 6 A promotes the translation of c-MYC, BCL2 and PTEN mRNAs in the human acute myeloid leukemia MOLM-13 cell line. Moreover, loss of METTL3 leads to increased levels of phosphorylated AKT, which contributes to the differentiation-promoting effects of METTL3 depletion. Overall, these results provide a rationale for the therapeutic targeting of METTL3 in myeloid leukemia.
A recently identified regulator of differentiation is N 6 -methyladenosine (m 6 A), a reversible nucleotide modification detected in at least 20% of mouse and human cellular mRNAs in diverse cell types 1, 2 . Embryonic stem (ES) cells deficient in Mettl3-the m 6 A RNA methyltransferaseremain pluripotent despite treatment with diverse stimuli that promote differentiation 3, 4 . Mettl3 -/-ES cells retain pluripotency markers and fail to acquire gene expression patterns seen in differentiated cells. By contrast, more-differentiated stem cells, such as primed stem cells, a cell type that is unable to contribute to embryonic development, show enhanced and abnormal expression of differentiation markers upon the depletion of m 6 A (ref. 3) . Overall, these data suggest that alterations in m 6 A levels can markedly influence cell fate and differentiation status, but that these effects are dependent on the cellular context.
Hematopoiesis provides an ideal model system in which to explore differentiation states, because hematopoietic stem cells (HSCs) have well-defined developmental trajectories and the differentiation of HSPCs can be monitored and quantified. Additionally, abnormal or blocked differentiation is a common feature of myeloid hematological malignancies. Whether m 6 A influences normal hematopoiesis or the abnormal differentiation seen in AML is not known. Elevated expression of FTO, a demethylase originally thought to target m 6 A, was reported to enhance leukemic oncogene-mediated cell transformation and to inhibit all-trans-retinoic acid-induced differentiation in AML 5 . However, FTO is now known to demethylate the N 6 -2'-O-dimethyladenosine (m 6 A m ) modification in mRNA 5´ caps, and to have only negligible effects on m 6 A (ref. 6 ). Thus, the role of m 6 A in the balance of normal and malignant differentiation of myeloid cells remains unclear.
To examine the function of m 6 A in HSCs, we depleted the m 6 A 'writer' METTL3 using shRNA in human cord blood (CB)-derived showed increased m 6 A levels as compared to control cells ( Fig. 1f and Supplementary Fig. 1g-k) . Overexpression of wild-type METTL3, but not of METTL3-CD, promoted proliferation and colony formation ( Fig. 1g and Supplementary Fig. 1g-k) and significantly inhibited myeloid differentiation of HSPCs ( Fig. 1h and Supplementary Fig.  1g-k) . Additionally, Mettl3 mRNA, which was abundant in mouse HSCs and HPSCs, was expressed in lower amounts in mature differentiated myeloid cells (Supplementary Fig. 1l) . These data indicate that the level of METTL3 and its enzymatic activity are negatively correlated with the differentiation of normal myeloid cells.
Given that myeloid differentiation is frequently dysregulated in leukemia, we next determined whether METTL3 expression is altered in leukemia. METTL3 mRNA expression in human acute myeloid leukemia (AML) samples was significantly higher than in other cancer types ( Fig. 2a) . To further assess the relative abundance of METTL3 in myeloid leukemia, we examined METTL3 mRNA and protein levels in multiple leukemia cell lines in comparison to those in primary CB-derived CD34 + HSPCs. METTL3 mRNA was more abundant in AML cell lines than in CB-derived cells (8/11) ( Supplementary Fig.  2a ), as was METTL3 protein (11/11) ( Fig. 2b) . We found no substantial differences in METTL3 expression across multiple subtypes of AML in the BloodPool database 9 (Supplementary Fig. 2b ). CD34 + HSPCs. Two independent shRNAs resulted in efficient knockdown of METTL3 (shRNAs #9 and #12) ( Fig. 1a ) and in a reduction of global m 6 A levels ( Fig. 1b and Supplementary Fig. 1a ). METTL3depleted cells gave rise to significantly (P < 0.01) fewer colony-forming units (CFUs) in all lineages when the cells were plated in methylcellulose ( Supplementary Fig. 1b ). Loss of METTL3 also resulted in the inhibition of cell growth ( Fig. 1c ) without evidence of apoptosis ( Fig.  1d) . Additionally, we observed an increase in myeloid differentiation in METTL3-depleted cells after 7 d, as compared to control cells expressing a scrambled shRNA, as assessed by both flow cytometric markers (CD11b and CD14) and morphology ( Fig. 1e and Supplementary Fig.  1c-e ). Increased differentiation was confirmed by the rapid loss of the stem/progenitor cell surface marker CD34 in METTL3-knockdown cells (Supplementary Fig. 1f ). Taken together, these data suggest that METTL3 depletion enhances myeloid differentiation.
Next, we examined whether, conversely, METTL3 overexpression can inhibit differentiation. To test this, we transduced CB-CD34 + cells with retroviruses expressing GFP alone or with wild-type METTL3. To directly address the requirement of the catalytic activity of METTL3, we also overexpressed a catalytically dead mutant of METTL3 (METTL3-CD; residues 395-399: DPPW→APPA) 7, 8 . Cells expressing METTL3 but not those expressing METTL3-CD 
examined the rankings of m 6 A 'writers' and 'erasers' in a previously published genome-wide CRISPR-based screen that sought to identify genes essential for cell survival of 14 AML cell lines 14 . Whereas all members of the 'writer' complex, including METTL3, METTL14, WTAP and KIAA1429, scored highly (in the top 10%) in the essential gene list, the sole m 6 A eraser ALKBH5 showed no essentiality for leukemia cell survival ( Supplementary Fig. 3l,m) . Additionally, the depletion of FTO, which was previously shown to be required for AML survival 5 , did not show a substantial effect on AML cell viability across most of these cell lines. Overall, these data strongly implicate the entire m 6 A-writer complex in leukemia cell survival, but not the m 6 A eraser ALKBH5 or the m 6 A m eraser FTO. Next, we examined METTL3 expression in primary cells from individuals with AML. We observed higher METTL3 expression in three of three AML patient samples and one of three MDS patient samples, as compared to CB-CD34 + HSPCs (Fig. 2k) . In addition, we detected a substantial elevation in global m 6 A levels in primary AML cells as compared to healthy HSPCs (Fig. 2l) . METTL3 depletion by shRNA inhibited colony formation by primary AML cells (Fig. 2m,n and Supplementary Table 1 ). Although we were unable to measure m 6 A levels in this experiment owing to limiting cell numbers, depletion of METTL3 has been previously shown to correlate with m 6 A levels in diverse contexts 1,2 . In these experiments, the only colonies that survived at day 14 were composed of cells in which METTL3 was not depleted (Fig. 2n) . Taken together, these data indicate a requirement for m 6 A and METTL3 activity in patient-derived AML cells.
To identify mRNAs that are methylated in MOLM-13 cells, we mapped m 6 A at single-nucleotide resolution using m 6 A individual-nucleotideresolution cross-linking and immunoprecipitation (miCLIP) 15 . In line with our previous analysis, m 6 A sites were primarily found in both exons and 3´ UTRs (52.4% and 32.4%, respectively), with the highest enrichment of m 6 A residues located near the stop codon ( Fig. 3a and Supplementary Fig. 4a ). As in other cell types 15 , m 6 A was most commonly found in the canonical m 6 A motif DRACH (D = A, G, U; R = G, A; H = A, C, U), with GGACU being the most frequent sequence context. For genes with called m 6 A modifications, the frequency of m 6 A modifications per gene ranged from a single m 6 A per gene (observed for 2,034 genes) to ten or more m 6 A per gene (117 genes) ( Supplementary  Fig. 4b and Supplementary Table 2 ).
To determine how METTL3 depletion affects m 6 A-containing transcripts, we performed RNA-seq on MOLM-13 cells after METTL3 knockdown ( Supplementary Fig. 4c ). Consistent with the idea that m 6 A destabilizes mRNA 16 , transcripts with at least one called m 6 A site showed increased abundance following METTL3 depletion as compared to transcripts with no called m 6 A sites (Fig. 3b) . Moreover, the change in abundance was correlated directly with the number of m 6 A sites per transcript ( Supplementary Fig. 4c and Supplementary Table 3 ).
To determine whether m 6 A depletion alters the translation of mRNA in MOLM-13 cells, we performed Ribo-Seq 17 to determine ribosome occupancy on mRNAs ( Supplementary Fig. 4d ). We measured the translational efficiency for each mRNA, defined as the number of ribosome-protected fragments divided by the mRNA expression 17 . Although m 6 A-containing transcripts became more abundant upon METTL3 depletion, METTL3 depletion reduced their translational efficiency ( Fig. 3c, Supplementary Fig. 4d and Supplementary Table 4 ). A similar increase in mRNA abundance coupled with reduced translation was found upon depletion of METTL3 in HeLa cells ( Supplementary Fig.  4e,f) 18 .
To determine the functional pathways associated with m 6 A-marked mRNAs, we performed gene-set enrichment analysis (GSEA) 19 on all 4,733 curated gene sets in the Molecular Signatures Database (MSigDB, METTL3, the catalytic subunit of the methyltransferase, forms an obligate heterodimer with METTL14, which serves as an RNA scaffold platform and is important for substrate recognition [10] [11] [12] . METTL14 mRNA expression in AML was also significantly higher (P < 0.001) compared to expression levels in most other cancers, but was not substantially different from those in thyroid cancer or clear-cell renal carcinoma, and was lower in AML than in breast cancer ( Supplementary  Fig. 2c) . With a few exceptions, METTL14 protein was not more highly expressed in AML cell lines than in primary cord blood CD34 + HSPCs (Supplementary Fig. 2d ). In accordance with the increased levels of METTL3 in leukemic cells relative to normal cells, we found that m 6 A abundance in poly(A) mRNA was significantly higher in the MOLM-13 AML cell line than in CD34 + control cells (Fig. 2c) . These data suggest that elevated m 6 A might be crucial for the maintenance of a cell-undifferentiated state in myeloid leukemia.
To directly address the role of m 6 A in human myeloid leukemia cells, we examined the effect of METTL3 knockdown in MOLM-13 cells.
METTL3 knockdown significantly decreased m 6 A levels, blocked cell growth, induced differentiation, and resulted in increased apoptosis as compared to a control shRNA ( Fig. 2d-g and Supplementary Fig.  2e-g) . Similar effects of shRNA-mediated METTL3 depletion were seen in the NOMO-1 and NB4 AML cell lines ( Supplementary Fig. 2h-o) .
We next asked whether METTL3 is required for leukemogenesis in vivo. We transduced human leukemia MOLM-13 cells with METTL3 shRNA and transplanted these cells into immunodeficient recipient mice. As compared to MOLM-13 cells transduced with scrambled shRNA, METTL3-shRNA-expressing cells exhibited delayed leukemia development ( Fig. 2h) . Additionally, human leukemia cells isolated from mice transplanted with METTL3-shRNA-transduced cells had METTL3 levels equivalent to those in scrambled-shRNA-transduced cells ( Supplementary Fig. 2p ), indicating that METTL3-depleted cells underwent negative selection in vivo, and that cells that had escaped METTL3 knockdown account for the development of leukemia by METTL3-shRNA-transduced cells.
Next, we used an shRNA-resistant form of METTL3 to test whether the effects of METTL3 shRNA could be due to off-target effects. Expression of the shRNA-resistant form of METTL3 in METTL3-shRNA-transduced MOLM-13 cells substantially rescued both the apoptotic and differentiation phenotypes ( Supplementary Fig. 3a-f ). Additionally, in an independent approach, we depleted METTL3 in MOLM-13 cells by generating CRISPR-Cas9-mediated mutation of METTL3. As observed in the shRNA experiments, METTL3 depletion using two independent guide RNAs (gRNAs) led to increased differentiation and apoptosis ( Supplementary Fig. 3g-j) . These data support a requirement for METTL3 in maintaining the undifferentiated state and survival of myeloid leukemia cell lines.
To test whether the enzymatic activity of METTL3 is required for its ability to inhibit differentiation, we overexpressed wild-type METTL3 and METTL3-CD in MOLM-13 cells ( Fig. 2i) and found that only wildtype METTL3 promoted cell growth ( Fig. 2j) . To further evaluate the role of METTL3's enzymatic activity, we used a CRISPR-Cas9 strategy that targets specific functional protein domains and infers functional importance on the basis of negative selection 13 . We tested gRNAs targeting the transcriptional start site (TSS) or the enzymatic domain of METTL3 in mouse leukemia RN2 (MLL-AF9, NRAS G12D ) cells. Only cells transduced with gRNAs targeting the methyltransferase domain were negatively selected over time, indicating that the enzymatic activity of METTL3 is crucial for the survival of leukemia cells ( Supplementary  Fig. 3k ).
To provide additional evidence for the requirement of m 6 A and the RNA-methylation complex for the survival of leukemia cells, we Supplementary Table 11 ). (f) Gene-set enrichment analysis plots for METTL3-regulated genes, as determined by RNA-seq, translational efficiency (Ribo-seq) and m 6 A miCLIP profiling. Top, embryonic stem cell (ESC) gene set; bottom, gene set that is upregulated in differentiated monocytes as compared to hematopoietic stem cells (HSCs) (see Supplementary Table 10 ). Cntl, control scramble shRNA; ES, enrichment score. (g) Gene-set enrichment analysis for m 6 A-enriched transcripts in two AML patient-derived samples (AML_118_Dx and AML_141), as compared to m 6 A-enriched transcripts in MOLM-13 cells. m 6 A-enriched transcripts identified in AML patient-derived cells by MeRIP-seq were used for gene-set enrichment analysis against the ranked list of transcripts with m6A sites cells in a. (h) Heat map showing log 2 normalized protein abundance as assessed using a reverse-phase protein array (RPPA) in MOLM-13 cells 4 d after transduction with scramble (control) or METTL3-targeting shRNAs (sh9 and sh12). The normalized linear value of protein abundance was converted to a relative color scheme, as shown in the horizontal bar below (row min, minimum abundance; row max, maximum abundance). Only proteins with significantly altered expression between control (n = 3) and METTL3-targeting shRNAs (n = 6) are listed; proteins are ranked by the average of the ratio of the values of the control over the average of the METTL3-targeting shRNAs ranked from largest ratio value to smallest value (P < 0.01, two-tailed t test). categories that included apoptosis and DNA damage, cancer and MYCassociated gene sets (Fig. 3e,f and Supplementary Tables 11 and 12) . Interestingly, the monocytic differentiation gene set was enriched with genes that were reduced in their mRNA abundance but increased in their translational efficiency upon METTL3 depletion, as compared to the control ( Fig. 3f and Supplementary Table 11 ). However, this effect is likely to be indirect, as this gene set was not significantly (P = 0.259) enriched for genes containing m 6 A (Supplementary Fig. 4g ).
Nevertheless, this analysis suggests that genes associated with differentiation, cell survival and c-MYC are particularly affected by METTL3 http://www.broadinstitute.org/msigdb) combined with 92 additional relevant gene sets from our experimentally derived or published hematopoietic self-renewal and differentiation signatures 19, 20 . We performed GSEA using the ranked lists of m 6 A sites, differentially expressed genes, and translational efficiency upon METTL3 depletion. This analysis identified 44 overlapping gene sets ( Fig. 3d and Supplementary Tables  5-11 ). These common gene sets were (i) enriched for m 6 A targets; (ii) negatively enriched for genes upregulated upon METTL3 depletion; and (iii) negatively enriched for genes with reduced translational efficiency in METTL3-depleted cells. We then grouped these pathways into general METTL3 depletion using either METTL3-specific shRNA or sgRNA led to a marked increase in pAKT levels ( Fig. 4c-e ), in keeping with the RPPA data (Fig. 3h) . Conversely, overexpression of METTL3 reduced pAKT levels (Fig. 4f) . Interestingly, p-AKT levels were reduced in both the METTL3 and METTL3-CD overexpressing cells, suggesting that m 6 A-independent mechanisms may contribute to the reduction in p-AKT levels observed after METTL3 overexpression.
Previous studies have shown that forced AKT activation in mouse hematopoietic cells and MLL-AF9-transformed cells results in differentiation and a loss of self-renewal 27, 28 . Consistent with the concept that AKT activation contributes to the rapid differentiation observed in METTL3-depleted cells, treatment of MOLM-13 cells with small-molecule inhibitors of either PI3K (GDC0032) or AKT (GDC0068) partially blocked the differentiation effects elicited by METTL3 depletion (Fig.  4g,h and Supplementary Fig. 4d) .
Overall, our study demonstrates that the m 6 A modification is crucial for the control of hematopoietic cell differentiation, and that this regulation is disrupted in myeloid leukemia. Depletion of the m 6 A writer METTL3 in normal CD34-enriched CB cells resulted in reduced proliferation and increased differentiation as compared to nontargeting control shRNAs and CRISPR gRNAs. In myeloid leukemia cell lines, METTL3 depletion similarly caused differentiation, as well as an increase in apoptosis (Fig. 4i) .
Unlike in glioblastoma, where m 6 A depletion promotes tumorigenesis 29, 30 , we find that METTL3 and m 6 A maintains the undifferentiated leukemic phenotype. Our finding of a requirement for METTL3 in leukemia is consistent with previous findings suggesting that METTL3 is crucial for the proliferation of lung cancer cells 8 . Additionally, genetic alterations of genes encoding m 6 A-writer-complex proteins correlate with poorer prognosis in individuals with AML, as assessed through an analysis of the Cancer Genome Atlas Research Network (TCGA) data sets 31 . Future studies will determine whether elevated METTL3 expression is sufficient to drive the initiation of leukemia. Taken together, our data suggest that AML cells regulate their translational state through the methylation of specific transcripts, and that disruption of this process by depletion of METTL3 yields a translational program that promotes differentiation and apoptosis.
In view of our findings that leukemia cells show an elevated abundance of METTL3 as compared to normal hematopoietic cells, and that METTL3 depletion induces apoptosis in leukemia cells but not in normal hematopoietic cells, we suggest that inhibition of METTL3 could be exploited as a therapeutic strategy for myeloid malignancies. Future studies exploring the potential therapeutic effects of targeting METTL3, potentially in combination with current and emerging therapeutic agents such as chemotherapy, FLT3 and IDH inhibitors, should be explored.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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To assess the clinical relevance of the m 6 A profile determined in MOLM-13 cells, we mapped m 6 A in two patient-derived AML samples and compared the m 6 A-enriched transcripts in MOLM-13 cells to those in the primary patient-derived AML samples. In two independent patient-derived AML samples (AML_118_Dx (ref. 21 ) and AML_141 (ref. 22)), the mRNAs with the highest levels of m 6 A (top 300 targets) were enriched for the m 6 A targets in MOLM-13 cells (Fig. 3g) .
We next sought to understand how METTL3 depletion influences signaling pathways in AML cells. Using a reverse-phase protein array (RPPA), we compared signaling-protein levels in MOLM-13 cells expressing a control shRNA and either of two METTL3-specific shRNAs. Among the proteins with the most significant increases in protein abundance upon METTL3 depletion were the apoptosis mediators caspase-7, caspase-3 and BIM ( Fig. 3h and Supplementary Table 13 ). The abundances of p-AKT (AKT-pT308 and AKT-pS473) and RICTOR (Rictor-pT1135) were also significantly increased by METTL3 depletion (Fig. 3h and Supplementary Table 13 ), indicating that m 6 A depletion may activate the PI3K/AKT pathway.
We observed that m 6 A targets were enriched in gene sets associated with MYC and apoptosis, and that the c-MYC and BCL2 transcripts were among the genes with the highest number of called m 6 A sites in the leukemia transcriptome (20 and 16 sites, respectively, Supplementary Fig.  4b and 5a, and Supplementary Table 2) . The PTEN transcript, which encodes a negative regulator of p-AKT, has six called m 6 A sites, suggesting that the increase in p-AKT levels observed in RPPA data could be due to a reduction in PTEN translation efficiency in METTL3-depleted cells ( Supplementary Fig. 4b and 5a and Supplementary Table 2) . To further examine METTL3-mediated regulation of PTEN, c-MYC and BCL2, we first sought to confirm that m 6 A levels in the c-MYC, BCL2 and PTEN transcripts are reduced following METTL3 knockdown in MOLM-13 cells, using the technique of MeRIP-qPCR, which measures transcript levels in m 6 A immunoprecipitates. We found that knockdown of METTL3 reduced the enrichment of m 6 A at mapped sites in the c-MYC, BCL2 and PTEN transcripts ( Fig. 4a and Supplementary  Fig. 5b) .
Consistent with the notion that m 6 A sites control translational efficiency, we observed a reduction of c-MYC, BCL2 and PTEN protein expression after METTL3 depletion using METTL3-specific shRNA, despite a 2-to 5-log 2 fold increase in transcript levels (Fig 4b-d) .
Similarly, CRISPR-Cas9-mediated disruption of METTL3 reduced c-MYC, BCL2 and PTEN protein levels at day 3 after transduction of the sgRNAs (Fig. 4e) . However, the repressive effects of shRNA-mediated METTL3 knockdown on c-MYC and BCL2 protein levels were either diminished or reversed on day 4 after shRNA transduction of hairpin #12, indicating that translation of these proteins at this time point may no longer be repressed by m 6 A. Translation at the day-4 time point may be mediated by an alternative internal ribosome entry site (IRES)-mediated translational mechanism that induces c-MYC and BCL2 protein synthesis under conditions of apoptosis and stress [23] [24] [25] . Indeed, METTL3 depletion led to the induction of an apoptotic program, as indicated by an increase in BIM protein expression at both 3 d and 4 d post-transduction (Supplementary Fig. 5c ).
Conversely, overexpression in MOLM-13 cells of wild-type METTL3, but not catalytically inactive METTL3-CD, led to an increase in c-MYC, BCL2 and PTEN protein levels (Fig. 4f) , indicating that the translational activation of target genes by METTL3 is dependent on its ability to catalyze m 6 A formation. Overexpression of METTL3 and METTL3-CD also resulted in increased levels of METTL14 (Fig. 4f) , likely reflecting stabilization of METTL14 upon its binding to METTL3, as described previously 26 .
ONLINE METHODS
Purification, viral transduction and culture of cord blood-derived HSPC-CD34 + cells. All primary patient samples, unless otherwise noted, were collected under the Biospecimen collection/banking study 09-141. The use of the samples for research purposes is covered under the Biospecimen research protocol . For each purification of CD34 + HSPCs, five or ten mixed CB units (each unit from one healthy donor) was used. Mononuclear cells were isolated from CB using Hespan and Ficoll-Hypaque Plus density centrifugation, followed by positive selection using the Auto MACS Pro Separator and isolation Kit (Miltenyi). CD34 + cells were cultured in 80% Iscove's modified Dulbecco's medium (IMDM, Cellgro) and 20% BIT 9500 medium (Stem Cell Technologies), supplemented with SCF (100 ng/ml), FLT-3 ligand (10 ng/ml), IL-6 (20 ng/ml) and TPO (100 ng/ml), used as the basic media. CD34 + cells were transduced using high-titer retroviral and lentiviral supernatant and 8 µg/ml polybrene. To differentiate HSPCs, cells were cultured under myeloid-promoting conditions: SCF (100 ng/ml), FLT-3 ligand (10 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml), GM-CSF (20 ng/ml) and G-CSF (20 ng/ml). Cytokines were purchased from Peprotech, NJ.
Colony-forming unit (CFU) assay. 10 4 CD34 + transduced cells were plated (in duplicate) in methylcellulose (MethoCult H4434 Classic-Stem Cell Technologies). CFU colonies corresponding to erythroid progenitor cells (BFU-E and CFU-E), granulocyte-macrophage progenitor cells (CFU-GM, CFU-G and CFU-M), and multipotent granulocyte, erythroid, macrophage and megakaryocyte progenitor cells (CFU-GEMM) were scored 14 d after seeding.
Proliferation assay. Cells were transduced with viruses by spinfection of leukemia cells in RPMI with 10% FBS or CD34 + cells in basic media. After 48 h of infection, cells transduced with shRNAs targeting METTL3 (shRNAs #9: CCAGTCATAAACCAGATGAAA; #12:CGTCAGTATCTTGGGCAAGTT) or control scramble shRNA (Addgene #1864) were treated with 3 μg/ml puromycin in the case of leukemia cell transduction and 2 μg/ml puromycin in the case of CD34 + cell transduction. 2 d after puromycin selection, cells were plated at 250,000 cells/ml for the proliferation assay.
For overexpression experiments, CB-CD34 + cells and MOLM-13 cells were transduced with MSCV-IRES-GFP (Addgene #20672) retrovirus expressing Flag-METTL3 or Flag-METTL3-CD or empty vector as control. METTL3 was sub-cloned into MSCV vector from pcDNA3 construct. METTL3-CD MSCV construct was created using QuikChange II Site-Directed Mutagenesis Kit (Agilent #200523). After 48 h of infection, cells expressing METTL3 or METTL3-CD were sorted on the basis of GFP positivity and plated at 250,000 cells/ml. Cells were counted at the indicated time points using a hemocytometer. All cell lines were purchased from ATCC, authenticated by Genetica and tested negative for mycoplasma contamination.
Flow cytometry. To monitor cellular differentiation status, cells were stained with the following antibodies: APC-CD11b (ThermoFisher, CD11b 05), APC-CD13 (ThermoFisher, MHCD1305), PE-CD14 (BD Pharmingen, 555398), PE-CD33 (BD Pharmingen, 555450). To measure apoptosis, cells were washed with PBS and incubated with anti-PE-Annexin V (BD Pharmingen, 556421) in the annexin-V binding buffer in a reaction volume of 100 µl for 15 minutes according to the manufacturer's instructions. DAPI was added prior to analysis. Cells were analyzed on a BD FACS LSR Fortessa instrument.
To monitor human leukemia cell engraftment, bone marrow cells from recipient mice were stained with APC-mouse CD45.1 (Biolegend 110720) and PerCP-Cyanine 5.5-human CD45 (eBioscience, 45-9459-42). Immunoblot analysis of engrafted human cells was performed using sorted human CD45-positive cells.
PI3K/AKT inhibitors. Prior to drug treatment, MOLM-13 cells were transduced using high-titer lentiviral-expressing control or METTL3 targeting short hairpin RNAs (shRNAs #9 and #12). 48 h after viral transduction, cells were selected using 3 µg/ml puromycin. After 24 h of selection, cells were treated with DMSO (vehicle), GDC0068 (1 µM) and GDC0032 (0.1 µM) for 48 h. Flow cytometry was then performed to evaluate cell differentiation using the CD11b and CD14 markers as described above.
Morphological analysis. 2 × 10 5 cells were centrifuged onto slides for 5 min at 500 r.p.m. and air-dried prior to GIEMSA staining. Cell morphology was evalu-ated by light microscopy by three people. Evaluators were not blinded to sample identity.
Immunoblot analysis. Cells were counted and washed twice with cold PBS prior to collection. ~250,000 cells were resuspended and lysed in 40 µl 1× Laemmli protein running buffer and boiled for 5 min. Whole-cell lysates were run on a 4%-15% gradient SDS-PAGE and transferred to a nitrocellulose membrane. Membranes were blotted with the following antibodies: METTL3 (Proteintech, 15073-1-AP), p-AKT(s473) (193H12 Cell Signaling, 4058s), c-MYC (D84C12 Cell Signaling, 5605s), PTEN (138G6 Cell Signaling, 9559s), BIM (C34C5 Cell Signaling, 2933), BCL2 (C-2 Santa Cruz, SC-7382), FLAG (F3165, Sigma-Aldrich) , METTL14 (HPA038002, Sigma-Aldrich) and actin (AC-15 Sigma-Aldrich, A3854). For miCLIP and MeRIP-qPCR, anti-N 6 -methyladenosine (Abcam, ab151230) was used. Uncropped western blots for all experiments are provided in Supplementary Figure 6 .
CRISPR-mediated deletion. For CRISPR-mediated deletion, MOLM-13-Cas9 cells (MOLM-13 cells engineered to constitutively express Cas9, obtained from the Daniel Bachovchin Laboratory at Memorial Sloan Kettering Cancer Center) were transduced with lentivirus pLKO5.sgRNA.EFS.GFP expressing sgRNAs targeting METTL3 (sgRNA#1 and sgRNA#2) or control GFP empty vector. sgRNAs were chosen for the highest score and fewest predicted off-target sites, as designed by MIT CRISPR Design (http://crispr.mit.edu). The sequences of sgRNAs were #1: TGTTAAGGCCAGATCAGAG; #2: CTGGGCTTAGGGCCACCAG. 5 d after sgRNA transduction, the pool of GFP-positive cells was gated by flow cytometry to assess apoptosis and differentiation as described for shRNAs transduced cells.
For the CRISPR domain-targeting assay, RN2c mouse leukemia cells constitutively expressing Cas9 (ref. 13) (obtained from Christopher Vakoc, Cold Spring Harbor Laboratories) were transduced with lentivirus pLKO5.sgRNA. EFS.GFP expressing sgRNAs targeting either the transcription start site (TSS) of mouse Mettl3 or the enzymatic domain of Mettl3 or with control GFP empty vector. sgRNAs were chosen for the highest score and fewest predicted off-target sites as designed by MIT CRISPR Design (http://crispr.mit.edu). Sequences of the sgRNAs are provided below. The percentage of GFP-positive cells were measured by flow cytometry 2 d post transduction (D0) and 17 d after plating (D17). SgRNAs were: mettl3-TSS-g#1: CACCGACTCGGCTCGAATCAGGCG; mettl3-TSS-g#2: CACCGATTCGAGCCGAGTCCGCGC; mettl3-TSS-g#3: CACCGGACACGTGGAGCTCTATCC; mettl3-enzymatic domain-g#1: CACCGTGTTGTGATATCCGCTACC; mettl3-enzymatic domain-g#2: CACCGTCACATGGAGCTACCGTAT; mettl3-enzymatic domain-g#3: CACCGCCACCTTGGGATATTCACA.
Sample preparation for miCLIP. m 6 A miCLIP was performed as previously described 15 , with the following modifications: total RNA from MOLM-13 cells was extracted using TRIzol (ThermoFisher) and treated with RQ1 RNase-free DNase I (Promega). Poly(A) RNA was then isolated using two rounds of selection with oligo(dT)25 magnetic beads (New England Biolabs). This resulted in 30 μg of poly(A) RNA for each replicate used in this study. Poly(A) RNA was subjected to fragmentation using RNA Fragmentation Reagents (ThermoFisher) for exactly 12 min at 75 °C. Fragmented RNA was then incubated with 15 μg of m 6 A antibody (Abcam) per replicate and the antibody-RNA complexes were processed by cross-linking, immunoprecipitation, RNA 3´ linker ligation, purification and reverse transcription exactly as previously described 15 . Generation of sequencing libraries was done in triplicate from separately purified poly(A) preparation.
Mapping of m 6 A sites. After sequencing, we used the miCLIP pipeline, as previously described 15 . In summary, raw miCLIP reads were trimmed of their 3´ adaptor and demultiplexed. Then, PCR-duplicated reads of identical sequences were removed using the pyDuplicateRemover.py script of the pyCRAC tool suite (version 1.2.2.3). Unique reads were mapped with Novoalign (v3.02.12) using hg19 as the reference genome. Further analysis including the identification of CITS was performed as previously described 15 . A custom script was then used to filter the identified putative m 6 A residues from the CITS file. This script filters C-to-T transitions on the basis of the number of transitions (m ≥ 2) and the transition frequency (1% ≥ m/k ≤ 50%) at any given coordinate. Additionally, we filtered for those called sites that have a DRACH sequence. These sites will be referred to as m 6 Corresponding author(s): Michael G. Kharas
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Experimental design 1. Sample size
Describe how sample size was determined. The sample size was chosen to have an estimated 80% power in detecting a greater than 1.50 s.d difference in means at a significance level of α = 0.05 using a two-sided t test.
For animal studies, survival probabilities were estimated using the Kaplan-Meier method and compared with the log-rank test. Eight mice per group were chosen to have an estimated 80% power in detecting a greater than 1.3 s.d. difference in means at a significance level of α = 0.05 using a two-sided test.
Data exclusions
Describe any data exclusions.
No data was excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All repeats were included in the study. Replication attempts were all successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
All animals were randomly assigned to the experimental groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not applicable for the study. Genetics manipulation (knock down, knock out) was performed and authors were always aware of experimental groups.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
